Survey Study About Endoscopy During COVID-19 Pandemic for IBD Doctors
Patterns of Endoscopy During COVID-19 Pandemic: a Global Survey of Interventional Inflammatory Bowel Disease Practice
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Hangzhou
-
Zhengzhou, Hangzhou, China, 310000
- Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Doctors who are involved in the endoscopic treatment of IBD patients;
- The endoscopist reads and signs an informed consent online. -
Exclusion Criteria:
- Doctors who are not involved in the endoscopic treatment of IBD patients
- Doctors who need the help of an agent, a witness, or someone else who can not complete the questionnaire independently.
- Other conditions that the researchers considered unsuitable for inclusion or influenced the participants'ability to complete the study.-
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
one group that is IBD endoscopist who perform the endoscopy for IBD patients
Complete the questionnaire online
|
IBD doctors who perform the endoscopy perform the questionnaire
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The influence of covid-19 pandemic on endoscopic practice by IBD endoscopist
Time Frame: 1 week
|
The incidence of scheduled IBD endoscopies were postponed or cancelled due to the pandemic.
|
1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of COVID19 in IBD patients who underwent endoscopy
Time Frame: 1 week
|
The percentage of IBD patients who underwent endoscopy since the outbreak was tested positive for COVID 19
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yan Chen, 浙江大学医学院附属第二医院
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- COVID-19
- Inflammatory Bowel Diseases
- Intestinal Diseases
Other Study ID Numbers
Other Study ID Numbers
- I2020001357
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.